Skip Navigation


American Journal of Epidemiology Advance Access originally published online on October 12, 2005
American Journal of Epidemiology 2005 162(10):1033-1035; doi:10.1093/aje/kwi319
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
162/10/1033-a    most recent
kwi319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Noord, P. A. H.
Right arrow Articles by van der Tweel, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Noord, P. A. H.
Right arrow Articles by van der Tweel, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A.

Letter to the Editor

RE: "USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION"

Paulus A. H. van Noord1 and Ingeborg van der Tweel2

1 Julius Center, Universitaire Medisch Centrum Utrecht, 3508 GA Utrecht, the Netherlands
2 Center for Biostatistics, Utrecht University, 3508 TC Utrecht, the Netherlands

P.A.H.vanNoord@UMCUtrecht.nl

The first 10% of the full text of this article appears below.

We read the article by Kpozèhuoen et al. (1Go) in the March 15, 2005, issue of the Journal with interest. As a methodological exercise, their Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method (2Go, 3Go), we performed a sequential statistical analysis . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?